Edwards Lifesciences Corporation
EW
Rang in aandelen
#489
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Aandeelprijs
$86.46
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$49.82B
Verandering (1 dag)
-1.75%
Verandering (1 jaar)
15.84%
Land
US
Handel Edwards Lifesciences Corporation (EW)
Categorie
Healthcare
Operationele marge voor Edwards Lifesciences Corporation (EW)
Operationele marge op October 2026 TTM: 28.09%
Volgens de meest recente financiële rapporten en aandelenkoers van Edwards Lifesciences Corporation is de huidige operationele marge (TTM) 28.09%. Eind 2024 had het bedrijf een operationele marge van 25.35%.
Geschiedenis van de operationele marge van Edwards Lifesciences Corporation van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 28.09% | -2,630.63% |
| 2025 | -1.11% | -104.38% |
| 2024 | 25.35% | -11.02% |
| 2023 | 28.49% | -9.93% |
| 2022 | 31.63% | 2.76% |
| 2021 | 30.78% | 4.16% |
| 2020 | 29.55% | 7.26% |
| 2019 | 27.55% | -6.10% |
| 2018 | 29.34% | -0.20% |
| 2017 | 29.40% | 6.83% |
| 2016 | 27.52% | 19.19% |
| 2015 | 23.09% | 10.11% |
| 2014 | 20.97% | -0.94% |
| 2013 | 21.17% | 1.39% |
| 2012 | 20.88% | 6.48% |
| 2011 | 19.61% | 0.46% |
| 2010 | 19.52% | 10.72% |
| 2009 | 17.63% | 4.38% |
| 2008 | 16.89% | 8.76% |
| 2007 | 15.53% | -1.52% |
| 2006 | 15.77% | -10.40% |
| 2005 | 17.60% | 6.15% |
| 2004 | 16.58% | 3.11% |
| 2003 | 16.08% | 117.30% |
| 2002 | 7.40% | 113.26% |
| 2001 | 3.47% | -70.64% |
| 2000 | 11.82% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 17.03% | -99.39% |
US
|
|
| 17.86% | -99.36% |
IE
|
|
| 22.03% | -99.22% |
US
|
|
| 21.46% | -99.24% |
US
|
|
| 0.00% | - |
DE
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.